All In MedTech

Device Trial Radar · NCT07796061

Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

A Safety and Feasibility Study to Evaluate Blood-Brain Barrier Disruption Using Exablate MR-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With Preferentially Expressed Antigen of Melanoma (PRAME), Survivin, and Wilms Tumor 1 (WT1)-Targeting Tumor Associated Antigen-specific T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2031

Study completion Dec 2032

Sponsor

Lead sponsor
Children's National Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Focused Ultrasound Foundation
First posted
Aug 31, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 3 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for Diffuse Midline Glioma (DMG), an aggressive brain tumor with a very poor prognosis - an average one-year overall survival. This study combines blood-brain barrier (BBB) disruption (BBBD) using low-intensity focused ultrasound (LIFU) and microbubble treatment, and intravenous infusion of autologous, tumor multi-antigen associated specific cytotoxic T lymphocyte (TAA-T) therapy. The TAA-T cell investigational product in this protocol is manufactured to target Preferentially Expressed Antigen of Melanoma (PRAME), Wilms Tumor 1 (WT1), and survivin.

Conditions

  • DMG
  • DIPG

Interventions

  • TAA-T CellBiological

    Intravenous tumor associated antigen specific T cell (TAA-T) infusion.

  • BBB DisruptionDevice

    BBB disruption using the Exablate 4000 Type 2 System with DEFINITY microbubbles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EvaluationTime frame: Within 28 days from last treatment
  2. Feasibility evaluationTime frame: Within 28 days from last treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.